Welcome Back, Pharmalot

The Wall Street Journal revives the popular blog covering pharmaceutical and biotech industry news.

By | June 4, 2014

FLICKR, VELKR0Ed Silverman’s Pharmalot blog is back, with a new home at The Wall Street Journal. Earlier this year (January 2), the blog was shut down by its former parent company, UBM Canon, which shuttered a handful of websites including PharmaLive.com, on which Pharmalot once resided.

In a June 3 post, Silverman said he will continue to cover the pharmaceutical and biotech industries as he has in the past. “And the subject matter will continue to touch on many topical bases—successes and failures as told by executives and patients; R&D challenges; patent skirmishes; marketing wars; government oversight; the use of social media and pricing tussles with payers, to name a few,” he wrote.

Silverman is still sharing industry news on Twitter, @pharmalot.

Clarification (June 5): The subheading on this article has been updated to reflect that the Pharmalot blog is back but was not bought.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Sequencing Reveals Genomic Diversity of the Human Brain
  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech